Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. (Nasdaq: GH) is a precision oncology company that regularly issues news about its blood and tissue tests, real-world data initiatives, and AI analytics in cancer care. This news page aggregates company announcements, press releases, and other updates so readers can follow how Guardant’s technologies are being used in screening, monitoring, and treatment selection for cancer.
Recent Guardant Health news has covered topics such as preliminary financial results and test volumes, payer coverage milestones for the Shield blood test for colorectal cancer screening, and collaborations aimed at expanding access to oncology clinical trials. The company also reports on scientific presentations that highlight the performance of Guardant Reveal for minimal residual disease detection and therapy response monitoring, and Guardant360 Liquid for multiomic profiling and breast cancer subtyping.
Guardant’s updates frequently describe how its tests are applied across all stages of care, including early detection, recurrence monitoring, and advanced cancer management. News items also include information about partnerships with hospitals and research centers, participation in healthcare and investor conferences, and initiatives related to data infrastructure and AI-ready environments for large-scale genomic datasets.
Investors, clinicians, researchers, and others interested in Guardant Health can use this page to review the company’s latest press releases and historical announcements. By browsing this feed, readers can see how Guardant’s portfolio of liquid biopsy and precision oncology diagnostics is being deployed in clinical practice, research collaborations, and broader efforts to improve access to cancer screening and personalized treatment.
Guardant Health (Nasdaq: GH) is expanding its Clear Your View campaign to raise awareness for complete biomarker testing in newly diagnosed advanced colorectal cancer (CRC) patients. Despite guidelines recommending testing for six biomarkers, over 60% of patients do not receive complete testing, risking suboptimal therapy. The initiative encourages oncologists to “stop, test, and wait” for testing results to increase treatment efficacy. The campaign is supported by various patient advocacy groups and emphasizes the importance of personalized treatment to improve survival rates.
Guardant Health (Nasdaq: GH) has achieved CE-marking for the Guardant360® CDx test, which profiles tumor mutations in patients with any solid malignant neoplasm. This test is also approved as a companion diagnostic for non-small cell lung cancer patients with EGFR alterations, indicating suitability for Tagrisso® (osimertinib) treatment. CE-marking enhances global accessibility of Guardant360 CDx, crucial for guiding personalized cancer treatments based on comprehensive genomic profiling. The test complements Guardant Health's mission to advance precision oncology.
Guardant Health reported a 25% increase in Q4 revenue to $78.3 million and a 34% yearly increase to $286.7 million in 2020. Notably, precision oncology revenue grew 31%, supported by a 70% rise in clinical testing. The company launched Guardant Reveal and expanded its partnership with Vall d’Hebron Institute of Oncology. Despite these gains, operating expenses surged 110% to $141.1 million in Q4, leading to a net loss of $93.7 million. Looking ahead, Guardant expects 2021 revenue between $360 million and $370 million.
Guardant Health (Nasdaq: GH) announces its participation in two upcoming virtual investor conferences. The 10th Annual SVB Leerink Global Healthcare Conference will feature a fireside chat on February 26 at 1:20 p.m. PT. Additionally, the Cowen 41st Annual Health Care Conference will hold a fireside chat on March 2 at 8:10 a.m. PT. Interested parties can access live and archived webcasts on the company’s website. Guardant Health is a leader in precision oncology, focusing on blood tests and advanced analytics to improve cancer patient outcomes and lower healthcare costs.
Guardant Health, Inc. (Nasdaq: GH) will report its fourth quarter and full year 2020 financial results after the market closes on February 24, 2021. A conference call to discuss these results will follow at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time, available for live streaming on the company’s website. Guardant Health is at the forefront of precision oncology, providing proprietary blood tests and advanced analytics to improve cancer care and outcomes. Their tests include Guardant360® and GuardantOMNI®, aiming to enhance early-stage cancer detection and management.
Guardant Health (Nasdaq: GH) reported findings from a study in JCO Precision Oncology demonstrating that its Guardant360 liquid biopsy detects 23.6% more actionable mutations compared to tissue biopsies for advanced non-small cell lung cancer (NSCLC). In a cohort of 186 patients, the liquid biopsy showed similar treatment responses and progression-free survival. The study advocates for a 'blood-first' approach, addressing challenges like insufficient tissue samples which affect 30% of patients. CEO Helmy Eltoukhy emphasized the need for broader adoption of liquid biopsies following recent FDA approval for the Guardant360 CDx test.
Guardant Health, Inc. (Nasdaq: GH) and Vall d’Hebron Institute of Oncology (VHIO) have formed a partnership to establish liquid biopsy testing services at VHIO's facility in Barcelona, Spain. This service aims to enhance access to genomic testing for cancer patients, starting with private patients and expanding to the public healthcare system. The partnership will support clinical trial eligibility assessments and accelerate cancer therapeutics research. Guardant Health's tests are backed by extensive clinical evidence and have received both CE mark and U.S. FDA approvals.
Guardant Health (Nasdaq: GH) will showcase significant data on its blood tests at the virtual 2021 ASCO Gastrointestinal Cancers Symposium from January 15-17, 2021. The presentations will focus on the clinical utility of Guardant’s liquid biopsy technology in screening and treating colorectal cancer. CEO Helmy Eltoukhy emphasized the importance of these tests in tracking treatment responses and early detection of cancer recurrence. Notable highlights include the Guardant Reveal™ test and the LUNAR-2 ECLIPSE trial aimed at early detection in average-risk adults.
Guardant Health (Nasdaq: GH) announced its participation in the 39th Annual J.P. Morgan Virtual Healthcare Conference, scheduled for January 11 at 7:50 a.m. PT / 10:50 a.m. ET. The event will feature a presentation by the company's management, accessible via a live and archived webcast on their website. Guardant Health specializes in precision oncology, offering blood tests and analytics that enhance cancer care. Their platforms, including Guardant360® and GuardantOMNI®, focus on advanced cancer treatment and early detection strategies.
Guardant Health, Inc. (Nasdaq: GH) has appointed Michael Bell as its new Chief Financial Officer (CFO), effective January 5, 2021. He succeeds Derek Bertocci, who retired after four years with the company. Bell brings over 25 years of finance experience from companies such as CareDx and Novartis Diagnostics. CEO Helmy Eltoukhy emphasized Bell's capability to enhance the company's financial operations and support its goal of transforming cancer care. Guardant Health specializes in precision oncology through proprietary blood tests and advanced analytics.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
